Consensus is for FY25 revenue $5.13B. Reaffirms FY25 GAAP Operating Expenses view $4.1B-$4.4B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines reports Q2 EPS 6c vs. (9c) last year
- BeOne Medicines granted PRIME designation for BGB-16673 by EMA
- BeOne Medicines reports positive opinion from CHMP regarding TEVIMBRA
- BeOne Medicines price target raised to $345 from $321 at JPMorgan
- BeOne Medicines price target raised to $349 from $311 at RBC Capital